GetTopicDetailResponse(id=1c855620260, topicName=拓?fù)涮婵? introduction=拓?fù)涮婵? content=null, image=null, comments=3, allHits=2011, url=https://h5.medsci.cn/topic?id=56202, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=19812, tagList=[TagDto(tagId=19812, tagName=拓?fù)涮婵?], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2241985, encodeId=e690224198526, content=廣泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小細(xì)胞肺癌#</a>的標(biāo)準(zhǔn)一線治療是鉑類與<a href='/topic/show?id=c62a268958c' target=_blank style='color:#2F92EE;'>#依托泊苷#</a>，聯(lián)合PD-L1抑制劑。二線治療則是<a href='/topic/show?id=1c855620260' target=_blank style='color:#2F92EE;'>#拓?fù)涮婵?</a>和<a href='/topic/show?id=aef712222ee9' target=_blank style='color:#2F92EE;'>#魯比奈克汀#</a>。二線治療的中位無進(jìn)展生存時間為3.5個月。
<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗體偶聯(lián)藥物#</a><a href='/topic/show?id=174e1222167d' target=_blank style='color:#2F92EE;'>#ABBV-011#</a>是針對SEZ6的抗體偶聯(lián)藥，總體的治療緩解率為25%，也就是25%的患者腫瘤病灶縮小超過30%，中位緩解持續(xù)時間為4.2個月，中位無進(jìn)展生存時間為3.5個月。
從這里來看ABBV-011仍然沒有什么突破性進(jìn)展，后續(xù)2，3期臨床還能否達(dá)到這樣的效果，還不好說。
總的一句話，小細(xì)胞肺癌，真的太難太難。, objectTitle=治療小細(xì)胞肺癌的抗體偶聯(lián)藥ABBV-011，首次人體臨床試驗結(jié)果公布了！, objectType=article, longId=852947, objectId=c38885294edf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240709/1720491961813_92910.png, objectUrl=/article/show_article.do?id=c38885294edf, replyNumber=0, likeNumber=62, createdTime=2024-12-12, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=c38885294edf, moduleTitle=治療小細(xì)胞肺癌的抗體偶聯(lián)藥ABBV-011，首次人體臨床試驗結(jié)果公布了！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c38885294edf)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2205358, encodeId=e5972205358b1, content=<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小細(xì)胞肺癌#</a> <a href='/topic/show?id=1c855620260' target=_blank style='color:#2F92EE;'>#拓?fù)涮婵?</a> <a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂質(zhì)體伊立替康#</a>, objectTitle=JCO | 脂質(zhì)體伊立替康與拓樸替康治療成人復(fù)發(fā)性小細(xì)胞肺癌的隨機、開放標(biāo)簽Ⅲ期臨床研究, objectType=article, longId=826358, objectId=d2c58263580e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240517/1715955785430_6145188.png, objectUrl=/article/show_article.do?id=d2c58263580e, replyNumber=0, likeNumber=107, createdTime=2024-05-18, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d2c58263580e, moduleTitle=JCO | 脂質(zhì)體伊立替康與拓樸替康治療成人復(fù)發(fā)性小細(xì)胞肺癌的隨機、開放標(biāo)簽Ⅲ期臨床研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d2c58263580e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2089214, encodeId=6afa20892144e, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>：<a href='/topic/show?id=377096965f6' target=_blank style='color:#2F92EE;'>#長春新堿#</a>-<a href='/topic/show?id=1c855620260' target=_blank style='color:#2F92EE;'>#拓?fù)涮婵?</a>-<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#環(huán)磷酰胺#</a>用于非轉(zhuǎn)移性<a href='/topic/show?id=f3934e272e8' target=_blank style='color:#2F92EE;'>#尤文氏肉瘤#</a>初始治療的III期臨床試驗結(jié)果，<a href='/topic/show?id=5f394e273fd' target=_blank style='color:#2F92EE;'>#尤文肉瘤#</a> (EWS) 是一種罕見的<a href='/topic/show?id=5a03104e94f1' target=_blank style='color:#2F92EE;'>#兒童惡性腫瘤#</a>, objectTitle=J Clin Oncol：長春新堿-拓?fù)涮婵?環(huán)磷酰胺用于非轉(zhuǎn)移性尤文氏肉瘤初始治療的III期臨床試驗結(jié)果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211017/1634453597626_2110107.JPG, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=236, createdTime=2022-09-20, rootId=0, userName=小小醫(yī)者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：長春新堿-拓?fù)涮婵?環(huán)磷酰胺用于非轉(zhuǎn)移性尤文氏肉瘤初始治療的III期臨床試驗結(jié)果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=901288, encodeId=a07a90128848, content=<a href='/topic/show?id=b03710396312' target=_blank style='color:#2F92EE;'>#貝洛替康#</a>有望代替<a href='/topic/show?id=1c855620260' target=_blank style='color:#2F92EE;'>#拓?fù)涮婵?</a>用于多種<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#實體瘤#</a>的化療, objectTitle=Br J Cancer：拓?fù)涮婵岛拓惵逄婵翟趶?fù)發(fā)性小細(xì)胞肺癌單一療法中的療效和安全性比較, objectType=article, longId=203653, objectId=a1a820365319, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201122/1606038741109_2467676.PNG, objectUrl=/article/show_article.do?id=a1a820365319, replyNumber=0, likeNumber=290, createdTime=2020-11-22, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1a820365319, moduleTitle=Br J Cancer：拓?fù)涮婵岛拓惵逄婵翟趶?fù)發(fā)性小細(xì)胞肺癌單一療法中的療效和安全性比較, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a1a820365319)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
